Full-Time

Principal Scientist CHO Cells

Media and Processes, X F M

Posted on 2/21/2026

Sartorius

Sartorius

5,001-10,000 employees

Laboratory instruments and bioprocess solutions

No salary listed

Paderborn, Germany + 1 more

More locations: Günzburg, Germany

Hybrid

Hybrid role with on-site in Bielefeld and occasional Ulm (or vice versa); some days remote; ~25% travel.

Category
Biology & Biotech (2)
,
Requirements
  • PhD in Science specializing in Biotechnology, Biochemistry, or a related field
  • several years of significant work experience in the biotech industry, ideally focusing on CHO processes and media, with both hands-on and strategic expertise
  • recognized expert (Key Opinion Leader, Subject Matter Expert) in CHO cell lines, processes, and cell culture media with proven track record including publications and patents
  • experience in Sartorius technology areas with proven track record
  • excellent written and verbal communication skills, English required and German desired
  • ability to prioritize multiple tasks and challenge existing systems and processes
  • creative and innovative thinking with strong communication and people/stakeholder management skills
  • good organization and time management abilities, ability to work under pressure, analytical and conceptual thinker
  • willingness to travel approximately 25%
  • identify with core values Sustainability, Openness and Joy
Responsibilities
  • Develop the strategy for the CHO upstream platform, especially for cell culture media and processes, consistent with Product and Technology Roadmaps and aligning with long-term objectives
  • Design and lead tactical plans based on Division/Corporate strategy, advising program leads and Senior Advanced Therapy Solutions leadership on strategic plans
  • Develop, collaborate, and influence internal and external expert committees on an international scale
  • Maintain technical expert relationships with CHO or media customers and research partners, ensuring effective customer communication
  • Establish new internal and external collaborations as well as development and research programs
  • Ensure successful technical application of research projects, particularly in key areas crucial for the technology base of Sartorius
  • Consult and advise a global team of Senior Scientists, Managers in R&D, Scientists, and Product Management
  • Evaluate, analyze, and present project results in internal and external meetings
  • Represent Sartorius as a Key Opinion Leader and Subject Matter Expert in Committees, Conferences, Panels, and Consortia
Desired Qualifications
  • German language skills (German desired)

Sartorius is a global partner in life sciences research and biopharmaceutical manufacturing. It provides laboratories with innovative instruments and consumables for research and quality control, and it offers Bioprocess Solutions focused on single-use systems that help manufacture biotech medicines, vaccines, and cell- and gene- therapies safely, quickly, and cost-effectively. Its products support the full path from drug discovery to commercial manufacturing, with a large worldwide footprint of more than 60 sites and a mission to help more people access better medicines. Sartorius differentiates itself through its broad portfolio spanning lab and bioprocess needs, a strong emphasis on single-use technologies, continuous portfolio expansion via acquisitions, and deep expertise serving pharmaceutical, biotech, and academic customers. Its goal is to simplify progress from research and development to scalable manufacturing so that life-saving medicines can reach patients worldwide.

Company Size

5,001-10,000

Company Stage

IPO

Headquarters

Göttingen, Germany

Founded

1870

Simplify Jobs

Simplify's Take

What believers are saying

  • Order intake hit highest Q4 2025 level, book-to-bill above one.
  • Equity ratio reached 48.7% after €1B capital increase in 2024.
  • 6-10% sales growth projected for 2026 with margins above 30%.

What critics are saying

  • Trump tariffs hit German imports; US manufacturing lags by 2027.
  • Danaher's Cytiva bundling steals share from Sartorius platforms.
  • Biotech funding drop 36% in 2024 cuts customer equipment capex.

What makes Sartorius unique

  • Sartorius leads in single-use ultrafilters like Sartocon Slice 50.
  • Ann Arbor $100M Center of Excellence boosts bioanalytics innovation.
  • SIMCA-online software excels in batch process monitoring.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Paid Holidays

Flexible Work Hours

Wellness Program

Professional Development Budget

Company News

The Associated Press
Mar 16th, 2026
Sartorius launches platform to cut CAR-T manufacturing costs by 90% and quadruple output

Sartorius has launched the Eveo Cell Therapy Platform, an integrated system for producing autologous cell therapies including CAR-T treatments. The modular platform can increase output up to fourfold in existing cleanroom space whilst reducing manufacturing costs by approximately 90 percent. The system integrates cell selection, activation, gene modification, expansion and final formulation into a closed system. Its compact design allows a single operator to process eight patient batches simultaneously in the space traditionally needed for two, potentially producing over 350 doses annually compared to today's 100 doses in the same footprint. A successful pilot with CDMO ElevateBio validated the platform's real-world applicability. Sartorius will begin taking orders in September 2026, with first deliveries expected in 2027.

Yahoo Finance
Feb 3rd, 2026
Sartorius grows revenue 7.6% to €3.5B with EBITDA margin expanding to 29.7%

Sartorius AG reported strong Q4 2025 results, with revenue growing 7.6% in constant currencies to over €3.5 billion, exceeding full-year guidance. The company's EBITDA margin expanded 170 basis points to 29.7%, whilst underlying net profit increased 18%. The bioprocess solutions division drove growth with 9.5% revenue increase in constant currency, supported by strong double-digit growth in recurring revenue. However, the lab products and services division remained essentially flat at 0.2% growth, facing challenges from unfavorable product mix. Sartorius improved its net debt to EBITDA ratio from 3.96 times to 3.55 times, demonstrating financial discipline. The company set a broad guidance range for 2026, citing macroeconomic volatility. Management noted that US onshoring initiatives are expected to impact revenue from 2027 onwards rather than 2026.

Yahoo Finance
Feb 3rd, 2026
Sartorius Stedim Biotech posts 18% profit growth despite equipment softness, cuts debt ratio to 3.55

Sartorius Stedim Biotech reported strong profit growth for Q4 2025, with revenue increasing 7.6% in constant currencies to over €3.5 billion. The EBITDA margin improved 170 basis points to 29.7%, whilst underlying net profit surged 18%. The bioprocess solutions division led growth at 9.5% in constant currency, driven by double-digit growth in recurring revenue that offset continued equipment softness. Order intake grew faster than sales, with the book-to-bill ratio remaining above one. Free cash flow reached €390 million, though operating cash flow declined to €837 million from €976 million previously. The net debt-to-EBITDA ratio improved from 3.96 to 3.55 times. However, the company faces headwinds from a weaker US dollar and set broad 2026 guidance due to market volatility.

Firmenpresse
Sep 16th, 2025
Repairon secures funding for heart therapy

Repairon GmbH, a German biotech company, has secured a substantial Series A funding for its innovative "heart patch" therapy aimed at treating advanced heart failure. The funding, led by Bioventure Management GmbH and co-invested by Satorius AG, will support the Phase 3 trial and GMP production scaling. The heart patch, made from engineered heart muscle, is applied to damaged heart tissue to restore function. Positive preclinical and Phase 1/2 results were published in Nature.

IT Juzi
Aug 12th, 2025
Nanotein secures $3M strategic investment

Nanotein, a cell therapy developer, has secured a $3 million strategic investment from Sartorius Stedim Biotech.

INACTIVE